Future pharmacologic targets for acute and preventive treatments of migraine (Q36106970)

12 August 2017

1 reference

title

Future pharmacologic targets for acute and preventive treatments of migraine (English)

1 reference

12 August 2017

Thomas M Buchanan

1

1 reference

PubMed ID

15853537

12 August 2017

Nabih M Ramadan

series ordinal

2

1 reference

PubMed ID

15853537

12 August 2017

Sheena Aurora

series ordinal

3

1 reference

12 August 2017

1 May 2004

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

3

1 reference

12 August 2017

391-430

1 reference

Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain.

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Study of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

CGRP may play a causative role in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

In-depth characterization of CGRP receptors in human intracranial arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Intranasal civamide for the treatment of episodic cluster headaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

The induction and maintenance of central sensitization is dependent on N -methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Glutamate receptors and nociception: implications for the drug treatment of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Nuclear factor-kappaB as a molecular target for migraine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Enhanced nitric oxide release during cortical spreading depression following infusion of glyceryl trinitrate in the anaesthetized cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Calcium channels and channelopathies of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Migraine prophylactic drugs: proof of efficacy, utilization and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

New and emerging prophylactic agents for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Divalproex sodium in migraine prophylaxis: a dose-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Mitochondria, magnesium and migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

Oxidative stress and platelet responsiveness in migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.391

21 January 2018

Identifiers

DOI

10.1586/14737175.4.3.391

1 reference

12 August 2017

1 reference

PubMed ID

15853537